Digital Life Line, a stepdown subsidiary DISA (SGX:532) unit DiSa Digital Safety, received an approval for the clinical deployment of its Automated Visual Acuity Test device at a hospital ophthalmology clinic in Hong Kong.
Initially, the device went through a successful three-month trial deployment at a public ophthalmology clinic in Hong Kong, according to a filing with the Singapore Exchange on Wednesday.
The device is aimed at combating myopia, which affects more than 40% of school children in Hong Kong.
Shares of the company surged 100% in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。